IDEAYA Biosciences (IDYA) Corporate presentation summary

Vision and strategy

• Aims to be a leader in precision medicine oncology, focusing on first- and best-in-class programs using predictive biomarkers and AI-driven drug discovery.

• Research targets rational drug combinations and multiple solid tumor indications, including neoadjuvant, adjuvant, and metastatic settings.

• Six internally discovered clinical-stage molecules address challenging targets like helicases, polymerases, and glycohydrolases.

• Integrated platform leverages CRISPR, chemigenomics, and computational drug discovery for pipeline renewal.

Clinical pipeline and focus areas

• Darovasertib targets uveal melanoma (UM), aiming to prolong survival and preserve vision.

• ADC + DDR combinations seek to improve efficacy and durability of TOP1 ADCs.

• MTAP pathway programs exploit synthetic lethality in ~15% of solid tumors.

• KAT6/7 inhibitors address tumor heterogeneity for enhanced treatment durability.

Uveal melanoma program (Darovasertib)

• UM is a rare, aggressive cancer with poor prognosis and limited treatment options; 50% progress to metastatic disease.

• Darovasertib is an oral PKC inhibitor targeting GNAQ/11 mutations, combined with crizotinib for metastatic UM.

• Phase 2/3 OptimUM-02 trial met its primary endpoint, doubling median PFS (6.9 vs. 3.1 months) and improving ORR and DCR.

• Early OS improvement trend observed; safety profile is manageable.

• Neoadjuvant studies show robust tumor shrinkage, eye preservation, and visual gains.

• Regulatory milestones include orphan drug, fast track, and breakthrough therapy designations.